Dataset

Identification of Multiple Sclerosis genetic markers leading to clinical benefits to affected patients

Bond University
Lotti Tajouri (Managed by)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=http://epublications.bond.edu.au/data/27/&rft.title=Identification of Multiple Sclerosis genetic markers leading to clinical benefits to affected patients&rft.identifier=http://epublications.bond.edu.au/data/27/&rft.publisher=Bond University&rft.description=  Multiple Sclerosis (MS) is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed. Data in SPSS software.&rft.creator=Anonymous&rft.date=2017&rft.relation=http://works.bepress.com/lotti_tajouri/21/&rft_rights=&rft_subject=110703, 110602, 100706&rft.type=dataset&rft.language=English Go to Data Provider

Please use the contact information below to request access to this data.

Licence & Rights:

No Licence view details
No licence

Access:

Other view details

Contact Lotti_Tajouri@bond.edu.au to determine access conditions.

Contact Information

Lotti_Tajouri@bond.edu.au

Bond University, Gold Coast, Queensland, 4229 Australia

Brief description

 

Multiple Sclerosis (MS) is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed.

Data in SPSS software.

Created: 2011

Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Similar datasets you may be interested in: